Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Key therapeutic areas
Autoimmune disorders
Cardiovascular diseases
Genetic disorders
Hematological disorders
Metabolic disorders
Ophthalmic disorders
Oncological disorders
Others
- Type of vector
- Adeno associated virus
- Adenovirus
- Herpes simplex virus type 1
- Lentivirus
- Plasmid DNA
- Retrovirus
- Vaccinia Virus
Type of therapy
- Ex vivo
- In vivo
Type of gene modification
- Gene augmentation
- Immunotherapy
- Oncolytic therapy
- Others
Route of administration
- Intraarticular
- Intracerebellar
- Intramuscular
- Intradermal
- Intravenous
- Intravitreal
- Intravesical
- Subretinal
- Others
Key geographical regions
North America
Europe
Asia-Pacific
The report includes detailed transcripts of discussions held with the following experts:
- Adam Rogers (CEO, Hemera Biosciences)
- Al Hawkins (CEO, Milo Biotechnology)
- Buel Dan Rodgers (Founder & CEO, AAVogen)
- Cedric Szpirer (Executive & Scientific Director, Delphi Genetics)
- Christopher Reinhard (CEO and Chairman, Cardium Therapeutics)
- Ryo Kubota (Chairman, President and Chief Executive Officer, Acucela)
- Jeffrey Hung (CCO, Vigene Biosciences)
- Marco Schmeer (Project Manager) & Tatjana Buchholz (Marketing Manager, PlasmidFactory)
- Michael Triplett (CEO, Myonexus Therapeutics, acquired by Sarepta Therapeutics)
- Robert Jan Lamers (CEO, Arthrogen)
- Tom Wilton (Chief Business Officer, LogicBio Therapeutics)
To request sample pages, please visit this – https://www.rootsanalysis.com/reports/268/request-sample.html
Key Questions Answered
- Who are the leading industry players in this market?
- How big is the development pipeline and which new indications are coming in focus? Which vectors are being used for effective delivery of the therapeutic agents?
- Who are the key investors in the gene therapy market?
- How is the current and future market opportunity likely to be distributed across key market segments?
- What kind of commercialization strategies are being adopted by gene therapy developers?
- What are the different pricing models and reimbursement strategies used for gene therapies?
- What are the prevalent R&D trends related to gene therapies?
- What are the various technology platforms that are either available in the market or are being designed for the development of gene therapies?
- Who are the key CMOs / CDMOs that claim to supply viral / plasmid vectors for gene therapy development?
You may also be interested in the following titles:
- Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)
- CAR-T Therapies Market (2nd Edition), 2019-2030
- Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415